Search Results - "Livnat, Daniella"

Evaluation of Monoclonal Antibodies to Human Immunodeficiency Virus Type 1 Primary Isolates by Neutralization Assays: Performance Criteria for Selecting Candidate Antibodies for Clinical Trials by D'Souza, M. Patricia, Livnat, Daniella, Bradac, James A., Bridges, Sandra H.

“…A collaborative study was organized to identify monoclonal antibodies (MAbs) that may be broadly and potently neutralizing for a panel of human…”
Get full text

Can Immune Markers Predict Subsequent Discordance between Immunologic and Virologic Responses to Antiretroviral Therapy? Adult AIDS Clinical Trials Group by Spritzler, John, Mildvan, Donna, Russo, Aleksandra, Asthana, Desh, Livnat, Daniella, Schock, Barbara, Kagan, Jonathan, Landay, Alan, Haas, David W.

“…It is unclear why discordant immunologic and virologic responses occur during therapy for human immunodeficiency virus (HIV) infection. This study examined…”
Get full text

A survey of tuberculosis infection control practices at the NIH/NIAID/DAIDS-supported clinical trial sites in low and middle income countries by Godfrey, Catherine, Tauscher, Gail, Hunsberger, Sally, Austin, Melissa, Scott, Lesley, Schouten, Jeffrey T, Luetkemeyer, Anne F, Benson, Constance, Coombs, Robert, Swindells, Susan

“…Health care associated transmission of Mycobacterium tuberculosis (TB) is well described. A previous survey of infection control (IC) practices at clinical…”
Get full text

Three‐color supplement to the NIAID DAIDS guideline for flow cytometric immunophenotyping by Nicholson, Janet, Kidd, Pamela, Mandy, Francis, Livnat, Daniella, Kagan, Jonathan

Get full text

Lymphoma models for B-cell activation and tolerance. II. Growth inhibition by anti-mu of WEHI-231 and the selection and properties of resistant mutants by Scott, D W, Tuttle, J, Livnat, D, Haynes, W, Cogswell, J P, Keng, P

“…Regulation of the growth of murine B-cell lymphomas has been used as a model for tolerance induction. The inhibition by anti-immunoglobulin reagents of the…”
Get more information

Use of CD45 gating in three and four‐color flow cytometric immunophenotyping: Guideline from the national institute of allergy and infectious diseases, division of AIDS by Schnizlein‐Bick, Carol T., Mandy, Francis F., O'Gorman, Maurice R.G., Paxton, Helene, Nicholson, Janet K.A., Hultin, Lance E., Gelman, Rebecca S., Wilkening, Cynthia L., Livnat, Daniella

Get full text

Immunotherapy of murine leukemia. VII. Prevention of Friend leukemia virus-induced immunosuppression by passive serum therapy by Genovesi, E V, Livnat, D, Collins, J J

“…Previous studies have suggested that the passive therapy of Friend leukemia virus (FLV)-induced disease with chimpanzee anti-FLV serum operates by reducing the…”
Get more information

Immunotherapy of murine leukemia VI. Development of immunologic memory in mice protected against Friend leukemia virus-induced disease by passive serum therapy by Genovesi, E V, Livnat, D, Collins, J J

“…The resistance of DBA/2 mice to infection with a leukemogenic dose of Friend leukemia virus (FLV) as a result of the passive administration of chimpanzee…”
Get more information

Immunotherapy of murine leukemia. VIII. Efficacy of passive serum therapy of Friend leukemia virus-induced disease in immunocompromised mice by Genovesi, E V, Livnat, D, Collins, J J

“…Previous studies have demonstrated that the passive therapy of Friend murine leukemia virus (F-MuLV)-induced disease with chimpanzee anti-F-MuLV serum is…”
Get more information

Adoptive transfer of antiviral resistance by lymphoid cells from mice protected against Friend leukemia virus-induced disease by passive serum therapy by Collins, J J, Genovesi, E V, Livnat, D, Sanfilippo, F

“…Spleen and bone marrow cells from DBA/2 mice protected against infection with a leukemogenic dose of Friend leukemia virus (FLV) by passive therapy with…”
Get full text